Moderna’s stock tumbles after reported leak of data for cancer vaccine

Moderna's stock has taken a dive following reports that data for their experimental cancer vaccine, developed in collaboration with Merck, was leaked prematurely. This leak occurred just before the official Phase 3 data presentation at a major medical conference this weekend. The sudden drop in stock value reflects investor concerns about potential negative impacts from the early disclosure. The implications are significant as the vaccine represents a major step in cancer treatment, and the leak could affect the company's credibility and future partnerships.